Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.460
+0.030 (2.10%)
At close: Oct 19, 2026, 4:00 PM EDT
1.460
0.00 (0.00%)
After-hours: Oct 19, 2026, 4:00 PM EDT
Innate Pharma Market Cap
Innate Pharma has a market cap or net worth of $140.13 million as of October 19, 2026. Its market cap has decreased by 29.08% in one year.
Market Cap
140.13M
Enterprise Value
150.60M
1-Year Change
-29.08%
Global Rank
n/a
Country Rank
n/a
Category
ChartMarket Cap Chart
Since October 18, 2019, Innate Pharma's market cap has decreased from $480.08M to $140.13M, a decrease of -70.81%. That is a compound annual growth rate of -16.11%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 19, 2026 | 140.13M | -19.18% |
| Dec 31, 2025 | 173.38M | 4.71% |
| Dec 31, 2024 | 165.58M | -29.08% |
| Dec 29, 2023 | 233.49M | -17.19% |
| Dec 30, 2022 | 281.97M | -29.50% |
| Dec 31, 2021 | 399.94M | 19.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Oct 18, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Molecular Partners AG | 140.67M |
| Protara Therapeutics | 139.47M |
| Satellos Bioscience | 139.25M |
| Tiziana Life Sciences | 137.71M |
| Codexis | 136.33M |
| Canton Strategic Holdings | 136.26M |
| Jyong Biotech | 133.99M |
| Atrium Therapeutics | 133.08M |